IMR Press / FBL / Volume 4 / Issue 4 / DOI: 10.2741/panoskaltsis

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Human immunodeficiency virus and the hematopoietic repertoire: implications for gene therapy
Show Less
1 University of Rochester Medical Center, Hematology/Oncology Unit, 601 Elmwood Ave, Box 610, Rochester, NY 14642, USA
Academic Editors:Joseph Rosenblatt, Vicente Planelles
Front. Biosci. (Landmark Ed) 1999, 4(4), 457–467; https://doi.org/10.2741/panoskaltsis
Published: 1 May 1999
(This article belongs to the Special Issue Gene therapy approaches to HIV-1 Infection)
Abstract

The human immunodeficiency virus (HIV) infects primarily the hematopoietic and immune systems. At the onset of infection, an initial activation of the immune system occurs, with a subsequent suppression thereafter due to direct viral infection of cells, inhibitory effects of HIV proteins, an altered microenvironment with cytokine imbalance, and increased apoptosis of both infected and non-infected cells. The CD34+ hematopoietic stem cell, however, remains free of infection. Novel methods in gene therapy utilize viral vectors that can introduce genes with good efficiency into the non-dividing stem cell. Therefore, HIV-resistance genes can be introduced into stem cells using these vectors. This confers resistance to infection to their respective progeny, and concurrently allows for repopulation of the immuno-hematopoietic repertoire. Applications of this technology to the patient infected with HIV are discussed in the context of myeloablative therapy and stem cell rescue.

Keywords
HIV
Hematopoiesis
Bone Marrow
CD34+
Gene Therapy
Share
Back to top